Gilead Sciences (NASDAQ: GILD), Celgene (NASDAQ: CELG) and Biogen Idec (NASDAQ: BIIB) are often the top stocks that come to investors' minds when they're shopping around for biotech stocks. It comes as no surprise; after all, these stocks have allowed many active investors to make a killing on Wall Street.
Despite what the bears say, these stocks are poised for growth for their ability to acquire smaller stocks, and their wealth of resources to further the development of their pipeline drugs. They also tend to recover losses at a quicker pace from downdrafts.
Yet somewhere on the national market, there are also some small biotech stocks that are worthy of your attention for their huge upside potential. Below are the said stocks which you should consider following now:
1. ChemoCentrix, Inc. (NASDAQ: CCXI). Forbes.com columnist Bryan Rich lists ChemoCentrix as one of the top five stocks that are bound to triple their share prices within the year. Valued at $239.64 million, the company's share prices are on an uptrend, rising close to 10 percent within a day in mid-October, Zacks Equity Research noted. ChemoCentrix's shares closed on Tuesday at $5.53, marking a sharp jump from its volatile price range of $4.29 to $4.90, according to the research firm.
ChemoCentryx is focused on developing and marketing drugs for autoimmune diseases, inflammatory disorders and cancer, according to its website. The company recently announced the results of its Phase 1 clinical trial for its pipeline drug CCX507, which it found was "safe and well-tolerated" in participating patients. CCX507 is intended for use in the treatment of patients suffering from inflammatory bowel diseases (NYSEARCA:IBD) including ulcerative colitis, and primary sclerosing cholangitis (NASDAQ:PSC).
2. Cytodyn, Inc. (OTCQB: CYDY). Cytodyn, Inc. offers its stocks over-the-counter and has a market capitalization of $39.03 million. Based on Yahoo! Finance data, the company's share prices recently closed at $0.70. Make no mistake of dismissing this stock, however, as its share price has the potential to edge remarkably higher, especially when it launches its pipeline product PRO 140.
According to Cytodyn's website, PRO 140 is a humanized monoclonal antibody that is being tested in a weekly monotherapy trial for HIV patients. PRO 140 is not a drug and has "no known issues with toxicity," which makes it safer to use for patients, especially those with compromised organ function.
The Phase 2b clinical trial for PRO 140 has wrapped up recently with positive results, proving the efficacy of the antibody in prolonging drug holidays in patients without putting them at risk for viral rebound. The company is currently in talks with the FDA to commence Phase 3 of its clinical trials.
3. Biodel Inc. (NASDAQ: BIOD) is a biopharmaceutical company that is focused on developing diabetes drugs in the United States, according to 24/7 Wall Street. According to the website, financial services firm Ladenburg Thalmann "likes" Biodel Inc. and expects its share price to reach $6 within the year. The company's share price closed at $ 1.49 based on latest market data.
Biodel Inc. has several diabetes product candidates based on insulin and peptide hormones. According to the company, its proprietary insulin formulations are "more rapid-acting" than those existing in the market for Type 1 and Type 2 diabetes patients. The formulations, it said, are optimized to remain stable at room temperature and can be administered by caregivers without medical training as an antidote to patients suffering from "severe hypoglycemia, or very low concentrations of blood glucose."
The biotech stocks above present a revenue-generating opportunity for investors who can endure volatility. At their current stock prices, these stocks are definitely a bargain.